Insider buying last 90 days
No open-market insider purchases were filed for PACS in the last 90 days.
From Form 4 filings, dated to when each was filed.
PACS Group reported third-quarter 2026 results on 4 November, with revenue up 11.5% year-over-year to $1.5 billion and net income growth of 16.2% to $60.8 million, driven by same-store performance and strategic acquisitions. Following the results, the company raised its full-year revenue and adjusted EBITDA guidance, citing higher occupancy across established skilled nursing facilities. Separate coverage noted the addition of 43 facilities since the third quarter, including acquisitions in Florida, Texas and Eduro adding 8,400 beds, alongside CEO Jason Murray's stock sales disclosed on 7 November and a Form 144 filing by Mark Hancock proposing a sale of 186,696 shares valued at $9,418,383.80.
PACS closed at $48.77, down 1.7%, sitting above both its 50-day average of $44.73 and 200-day average of $40.07. The stock has returned 12.6% over one month and 290.8% over one year, with a 52-week range of $10.31 to $51.68. The GekkoIndex reads 51.6, placing it in the Neutral zone, while Gekko Fair Value stands at $50.37, putting the current price 3.2% below that level.
The next earnings date falls on 25 February 2027, 102 days away and outside a typical 20-trading-day holding window. Four analyst firms currently rate the stock buy, with a consensus target of $59 implying 21% upside. No insider, Congress or unusual options activity appears in the respective 90-day and 30-day windows, and insufficient history exists for a seasonal read. The gap to Gekko Fair Value bears watching given recent guidance raises and acquisition activity.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
PACS scores 3 supportive, 1 mixed and 0 headwinds across the 4 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed0 headwinds
Above 50 and 200-day
Close $48.32 is above the 50-day ($45.23) and 200-day ($40.36) averages, and the 50-day is above the 200-day.
See the chart56, Neutral
Reading 56 is in the Neutral zone.
See the GekkoIndex6.5% below
Price is 6.5% below Gekko Fair Value (more than 5% below).
See fair valueNo data
No insider, Congress or unusual options activity in the window.
See smart moneyReports in 102 days
Next report Feb 25, 2027, 102 days away — outside a typical 20-trading-day hold.
See earningsNo data
Not enough years of history for a seasonal read.
A description of current data, not a recommendation. How this page works
PACS closed at $48.32 on Nov 13, 2026, +321.6% over the past year, inside a 52-week range of $10.31 to $51.68.
Use the left and right arrow keys to read daily values.
Put PACS on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
PACS functions as a parent company overseeing a group of businesses centered on care for patients after hospital discharge or acute treatment. This work spans running care facilities, supplying trained clinical staff, and handling the supporting services those facilities need to function. It is also recognized for housing options aimed at older adults, including focused senior care, assisted living, and independent living settings offered in particular communities.
Its operations bring together two related strands, one centered on clinical and facility-driven care, the other on residential living for seniors, giving it a presence across multiple points in a person's care journey.
Jason Murray and Mark Hancock started the company in 2013, and it now runs its operations from Farmington, Utah. Its stock trades on the NYSE under the ticker PACS.
PACS’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 56, in the Neutral zone, up 6.4 points over five sessions.
Up 6.4 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 36 | +2.7% | +6.9% | ||
| Accumulation | 194 | +1.3% | +5.6% | ||
| Neutral (current zone) | 364 | +1.0% | +6.3% | ||
| Distribution | 44 | +1.6% | +1.1% | ||
| Selling | 4 | Too few readings yet | |||
Average PACS share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
PACS trades 6.5% below Gekko Fair Value of $51.67, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what PACS shares are worth, recalculated every trading day.
$51.67
Gekko Fair Value, Nov 14, 2026
6.5% Undervalued
At the end of Aug 2026 the price was 21.6% below the estimate.
No open-market insider purchases were filed for PACS, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for PACS in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in PACS were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
PACS has been buying back its own shares.
From company filings.
0of the funds Gekko tracks hold PACS.
PACS reports on Feb 25, 2027 (102 days away), and beat the EPS estimate in 5 of its last 8 reports.
Feb 25, 2027
102 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | $0.63 est $0.55 | $1.43B est $1.41B | +2.6% |
| May 11, 2026 | $0.64 est $0.41 | $1.42B est $1.36B | +22.1% |
| Feb 26, 2026 | $0.43 est $0.48 | $1.36B est $1.38B | −7.1% |
| Nov 19, 2025 | $0.32 est $0.45 | $1.34B est $1.11B | +81.2% |
| Aug 18, 2025 | $0.45 est $0.48 | — | +3.0% |
| May 19, 2025 | $0.42 est $0.40 | — | −2.5% |
| Feb 26, 2025 | $0.39 est $0.35 | — | −3.2% |
| Nov 8, 2024 | $0.34 est $0.33 | — | +10.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for PACS is $61.33, +26.9% from the last close, from 5 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 5 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 10 | Oppenheimer | $57 | +18.0% |
| Nov 5 | UBS | $67 | +38.7% |
| Nov 5 | Stephens | $64 | +32.5% |
| Oct 12 | UBS | $60 | +24.2% |
| Sep 8 | J.P. Morgan | $58 | +20.0% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
PACS’s market cap is $7.67B, with a P/E ratio of 27.3 and revenue of $5.71B over the last twelve months.
Coverage of PACS this week reads neutral: 2 positive, 2 neutral and 2 negative headlines.
PACS’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| HCAHCA Healthcare | Neutral | 26.1% above |
| THCTenet Healthcare | Neutral | 3.0% below |
| UHSUniversal Health Services | Neutral | 11.5% below |
| CHEChemed | Neutral | 2.8% below |
| SGRYSurgery Partners | Distribution | 45.2% above |
| NHCNational HealthCare | Accumulation | 18.9% above |
A peer links to its own page where one exists.
PACS’s market cap is $7.67B at the Nov 13, 2026 close of $48.32, with 158.7M shares outstanding. The shares trade on a P/E ratio of 27.3.
The consensus analyst 12-month price target for PACS is $61.33, +26.9% from the last close. Of the 5 firms that rated the stock in the last 90 days, 5 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate PACS is undervalued: the Nov 13, 2026 close of $48.32 is 6.5% below Gekko Fair Value of $51.67. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
PACS is expected to report on Feb 25, 2027 (102 days away). Analysts expect earnings of $0.61 per share on revenue of $1.64B. PACS beat the earnings estimate in 5 of its last 8 reports, moving 16.6% on average across the report.
PACS’s 52-week high is $51.68 and its 52-week low is $10.31; it closed at $48.32 on Nov 13, 2026, +321.6% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 4 items with data read as supportive (trend, fair value and earnings risk), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.